Cancer Research
– Results suggest that mesothelin-targeted TriKE can work alongside current standard of care and provide benefit even in the hypoxic environment of a solid tumor Excerpt from the Press Release: BRISBANE, Calif., March 9, 2022 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary tri-specific…
Read More
NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia Excerpt from the Press Release: CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative…
Read More
The Company Also Announced Immunotherapy Pioneer Dr. Michael Jensen as Founding Advisor Broad research collaboration focuses on BrainChild program, a suite of five multiplex chimeric antigen receptors (CARs) that initially targets pediatric central nervous system (CNS) malignancies with limited therapeutic options. Cellevolve will also leverage Seattle Children’s renowned Cure Factory® facility for early clinical Good…
Read More
– Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC – – PFS and OS benefits were observed across all PD-L1 expression subgroups, including in patients with low PD-L1 expression – Excerpt from the Press Release: REDWOOD CITY, Calif., and SHANGHAI, China, March 04, 2022 (GLOBE NEWSWIRE) —…
Read More
Following Discussion with the FDA, Karyopharm Plans to Initiate a New Placebo-Controlled Randomized Study of Selinexor in the Advanced or Recurrent Endometrial Cancer p53 Wild-Type Population to Support a Future sNDA Submission as the Current Topline Data from the SIENDO Study are Unlikely to Support an sNDA Approval Karyopharm is Encouraged by the SIENDO p53…
Read More
Excerpt from the Press Release: BEIJING, SHANGHAI and BOSTON, Feb. 23, 2022 /PRNewswire/ — Jacobio Pharmaceuticals (1167.HK) announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combination therapy with Cetuximab at Peking University Cancer Hospital recently. JAB-21822 in combination with cetuximab for the treatment of KRAS G12C-mutated advanced colorectal cancer. Colorectal cancer is the second most common tumor…
Read More
Ability to serially monitor treatment response, identify key biomarkers and customize assay aids clinical research efforts to improve treatment for metastatic cancers involving brain and spinal cord Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Feb. 22, 2022– Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, highlighted the ability of its CNSide™ cerebrospinal…
Read More
Excerpt from the Press Release: NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®. In a real-world analysis of 1,076…
Read More
Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency, KIMMTRAK will be the first and only treatment option approved in Europe to treat patients with unresectable or metastatic uveal melanoma KIMMTRAK demonstrated statistically and clinically meaningful overall survival (OS) benefit, hazard ratio of 0.51, with median OS of almost 22 months Excerpt from the…
Read More
Epic Sciences scales its workflow for ctDNA testing with Next Generation Sequencing Leader Fulgent Fulgent Genetics’ expertise in high-volume testing powers Epic’s Comprehensive Cancer Profiling Excerpt from the Press Release: SAN DIEGO, Feb. 24, 2022 /PRNewswire/ –Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast…
Read More